Last reviewed 2026-04-23 · How we verify

TQB2440 injection + Trastuzumab + Docetaxel

TQB2440 injection + Trastuzumab + Docetaxel is a Targeted therapy, monoclonal antibody, chemotherapy Small molecule drug developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. It is currently in Phase 3 development for Locally advanced or metastatic HER2-positive breast cancer, Locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.

TQB2440 injection is a targeted therapy that works by inhibiting the PD-1/PD-L1 pathway, while Trastuzumab is a monoclonal antibody that targets the HER2/neu receptor, and Docetaxel is a chemotherapy medication that works by inhibiting cell division.

TQB2440 injection is a targeted therapy that works by inhibiting the PD-1/PD-L1 pathway, while Trastuzumab is a monoclonal antibody that targets the HER2/neu receptor, and Docetaxel is a chemotherapy medication that works by inhibiting cell division. Used for Locally advanced or metastatic HER2-positive breast cancer, Locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.

At a glance

Mechanism of action

TQB2440 injection's mechanism of action involves binding to PD-1, preventing its interaction with PD-L1 and thereby unleashing the immune system to attack cancer cells. Trastuzumab, on the other hand, binds to the HER2/neu receptor on cancer cells, causing cell death. Docetaxel works by inhibiting the microtubule dynamics, which is essential for cell division, ultimately leading to cell death.

Approved indications

• Locally advanced or metastatic HER2-positive breast cancer
• Locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma

Common side effects

• Fatigue
• Nausea
• Diarrhea
• Neutropenia
• Thrombocytopenia

Key clinical trials

• Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer (PHASE3)
• Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer (PHASE3)
• Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer. (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• TQB2440 injection + Trastuzumab + Docetaxel CI brief — competitive landscape report
• TQB2440 injection + Trastuzumab + Docetaxel updates RSS · CI watch RSS
• Chia Tai Tianqing Pharmaceutical Group Co., Ltd. portfolio CI

Frequently asked questions about TQB2440 injection + Trastuzumab + Docetaxel

Related

• Drug class: All Targeted therapy, monoclonal antibody, chemotherapy drugs
• Target: All drugs targeting PD-1, HER2/neu
• Manufacturer: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — full pipeline
• Therapeutic area: All drugs in Oncology
• Indication: Drugs for Locally advanced or metastatic HER2-positive breast cancer
• Indication: Drugs for Locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma
• Compare: TQB2440 injection + Trastuzumab + Docetaxel vs similar drugs
• Pricing: TQB2440 injection + Trastuzumab + Docetaxel cost, discount & access